Section Editors

  • Michael Aschner, Vanderbilt University
  • Phil Biggin, University of Oxford
  • Lucio Guido Costa, University of Washington
  • David H Farb, Boston University School of Medicine
  • Piero Olliaro, World Health Organization
  • Giorgio Palu, University of Padova

Executive Editor

  • Christopher Morrey, BioMed Central

Articles

There has been an error retrieving the data. Please try again.
  • Image attributed to: Wikimedia Commons by National Human Genome Research Institute

    Nematode model of early exposure to genotoxicants

    Exposure of developing Caenorhabditis elegans to ultraviolet C radiation results in decreased ATP levels and oxygen consumption in later life, suggesting that early life contact with mitochondrial genotoxicants may lead to time-delayed mitochondrial dysfunction.

    BMC Pharmacology and Toxicology 2013, 14:9
  • Image attributed to: flickr by nic_r

    Toxicology at a crossroads

    Section Editors Lucio G. Costa and Michael Aschner provide their insights on recent developments in the field of toxicology and discuss their future aspirations for BMC Pharmacology and Toxicology.

    BMC Pharmacology and Toxicology 2012, 13:16
  • Image attributed to: From Wikimedia Commons by Fastily

    Can silkworms be used as model organisms?

    Silkworm larvae may represent a useful model of tissue injury induced by cytotoxic drugs through the measurement of alanine aminotransferase activity and could be useful in evaluating drug toxicity prior to tests in mammals.

    BMC Pharmacology and Toxicology 2012, 13:13
  • Image attributed to: Wikimedia Commons by Ring0

    Cocaine-induced modulation of Mu-opioid receptors

    Nitric oxide and histone deacetylase activity regulate cocaine-induced Mu-opioid receptor (MOR) expression at both transcriptional and post-transcriptional levels in PC12 cells, suggesting that epigenetic mechanisms modulate cocaine's action on MOR expression in vivo.

    BMC Pharmacology and Toxicology 2012, 13:11
  • View more articles  

RSS

Comments

View more comments

Scope

BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.

It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.

Editors' Profile

Lucio G. Costa and Michael Aschner

Lucio G. Costa and Michael Aschner

Lucio G. Costa (left) is currently Professor of Environmental and Occupational Health Sciences at the School of Public Health at the University of Washington. Dr Costa is a renowned neurotoxicologist whose research interests are focused on understanding the role of neurotoxic substances in neurodevelopmental disorders and other neurological, neuropsychiatric and neurodegenerative diseases. Michael Aschner (right) is the Gray E. B. Stahlman Professor of Pediatrics and Pharmacology at Vanderbilt University School of Medicine as well as a Senior Investigator at the Kennedy Center for Research on Human Development. Dr Aschner's research group has a particular interest in the neurobiology and physiology of astrocytes and the signaling mechanisms associated with central nervous system injury. Dr Costa and Dr Aschner are Section Editors for the Toxicology section in BMC Pharmacology and Toxicology. Read more about the key issues in this field and the manuscripts they would like to see submitted to the section in their interview with the journal.

"We are interested in original research and review papers that address the interactions of chemicals with biological systems. The manuscripts may include basic research of molecular mechanisms underlying normal and abnormal physiology to define novel therapeutic targets; translational research to adapt observations from the laboratory to patients; clinical research to examine the behavior of novel therapeutics in humans; basic research to identify molecular mechanisms and targets of xenobiotics; and population research to identify health outcomes associated with exposures to environmental agents and xenobiotics."

BMC Pharmacology

BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.

Latest supplements

Volume 13 Suppl 1 (17 September 2012)

18th Scientific Symposium of the Austrian Pharmacological Society (APHAR)

Meeting abstracts
Graz, Austria. 20-21 September 2012

View all supplements